Loading stock data…
Biodexa Pharmaceuticals Plc (BDRX)
$2.85-0.07 (-2.40%)
Market ClosedLast close Jun 29
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biodexa Pharmaceuticals Plc in the Healthcare sector is trading at $2.85 with a market capitalization of $2M. Wall Street consensus targets $35.16 (1 analysts), implying a +1133.8% move over the next 12 months. The stock is currently near its 52-week low of $2.45, remaining 80.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1133.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
105,354
Recent News
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
European equities traded in the US as American depositary receipts were trending higher late Monday
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European equities traded in the US as American depositary receipts were lower late Wednesday morning
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking sharply lower late
European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading
European equities traded in the US as American depositary receipts were down marginally late Thursda
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were marginally higher Tuesday mo